NFRP Outreach and Invitation for Response
ID: 327763Type: Forecasted
Overview

Buyer

Dept. of the Army -- USAMRAA (DOD-AMRAA)

Eligible Applicants

Unrestricted

Funding Category

Science and Technology and other Research and Development

Funding Instrument

Other

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/327763
Timeline
    Description

    The Department of the Army, through the US Army Medical Research Acquisition Activity (USAMRAA), is forecasting an opportunity for a Research-based Other Transactions Agreement (rOTA) under the Neurofibromatosis Research Program (NFRP). This initiative aims to accelerate the clinical translation of basic research related to neurofibromatosis (NF) by conducting collaborative Phase I and II clinical trials focused on promising therapeutic agents for NF1, NF2, and schwannomatosis. Historically, this requirement has been addressed through assistance agreements, and the government is now seeking feedback on this proposed approach, emphasizing the need for cost-sharing arrangements and access to patient populations. Interested parties can reach out to Jason D. Kuhns at jason.d.kuhns.civ@mail.mil for further information, as this outreach is for planning purposes and does not constitute a solicitation.

    Point(s) of Contact
    Jason D Kuhns Agreements Officer
    (301) 619-1861
    jason.d.kuhns.civ@mail.mil
    Files
    No associated files provided.
    Similar Opportunities
    Clinical Trials Addressing Unmet Needs of Rare Neurodegenerative Diseases (R01) Clinical Trials Required
    Food and Drug Administration
    The Food and Drug Administration (FDA) is forecasting a federal grant opportunity titled "Clinical Trials Addressing Unmet Needs of Rare Neurodegenerative Diseases (R01) Clinical Trials Required." This grant aims to fund clinical trials that evaluate the efficacy and safety of products intended to address unmet needs in rare neurodegenerative diseases affecting both children and adults, thereby increasing the number of approved treatments in this critical area. The initiative is part of the FDA's broader effort to enhance drug development for rare diseases, which is vital for improving health outcomes in affected populations. Interested applicants can reach out to Terrin Brown at terrin.brown@fda.hhs.gov or call 240-402-7610 for more information, with funding amounts ranging from $650,000 to $900,000 for the fiscal year 2025.
    DOD USAMRDC FY23-FY27 BROAD AGENCY ANNOUNCEMENT for Extramural Medical Research
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the U.S. Army Medical Research and Development Command (USAMRDC), has announced the FY23-FY27 Broad Agency Announcement (BAA) for Extramural Medical Research, which is open for submissions from October 1, 2022, to September 30, 2027. This opportunity invites innovative research proposals that address critical military medical challenges, particularly in the areas of Military Infectious Diseases, Combat Casualty Care, and Military Operational Medicine, with a focus on enhancing medical practices for both military personnel and civilians. The BAA emphasizes the importance of collaboration with Department of Defense and Department of Veterans Affairs resources and requires adherence to strict submission guidelines via Grants.gov and the electronic Biomedical Research Application Portal (eBRAP). Interested applicants can submit pre-proposals at any time during the five-year period, with full proposals invited based on initial submissions, and should direct inquiries to the CDMRP Help Desk at help@eBRAP.org.
    Request for Information – University Partnership Models
    Dept of the Army -- Materiel Command
    The Department of the Army's Materiel Command is issuing a Request for Information (RFI) to explore innovative university partnership models aimed at enhancing collaboration in science and technology to meet the future needs of the Army, particularly for 2040 and beyond. The Army Research Laboratory (ARL) seeks input from academic institutions on agile teaming approaches that can facilitate rapid access to a diverse range of expertise, focusing on both unclassified and classified challenges. This initiative is critical for establishing strategic relationships with universities to leverage their research capabilities effectively, thereby improving outcomes relevant to the Army's science and technology gaps. Interested parties must submit their responses by November 21, 2024, and can direct inquiries to Mr. Karl A. Kappra or Dr. David Stepp via email at UniversityRFI@army.mil.
    Request for Information Trusted Partner Program
    Dept of the Army -- Materiel Command
    The Department of the Army's Materiel Command is seeking feedback through a Request for Information (RFI) for its Trusted Partner Program (TPP), aimed at establishing a network of external academic partners capable of conducting basic scientific research. This initiative is designed to create multiple five-year Indefinite Delivery/Indefinite Quantity (ID/IQ) contracts to facilitate agile research and advanced technology development across various technical fields. The program is crucial for enhancing the Army's access to expert talent and expediting science-driven capabilities for national security. Interested institutions must demonstrate robust security clearances and research capabilities, with responses to the RFI due by December 31, 2025. For further inquiries, potential respondents can contact Meaghan Pimsler at DEVCOMARLTPP@army.mil.
    Reissue of RFA-FD-23-001- Clinical Studies of Orphan Products Addressing Unmet Needs of Rare Diseases (R01 Clinical Trials Required)
    Food and Drug Administration
    The U.S. Food and Drug Administration (FDA) has announced a Notice of Funding Opportunity (NOFO) titled "Reissue of RFA-FD-23-001 - Clinical Studies of Orphan Products Addressing Unmet Needs of Rare Diseases (R01 Clinical Trials Required)." This initiative aims to fund clinical trials that evaluate the efficacy and safety of orphan products for rare diseases, with the goal of addressing unmet medical needs and increasing the number of approved treatments in this area. The funding opportunity encourages innovative trial designs and collaboration among various stakeholders, emphasizing the importance of patient engagement throughout the research process. Eligible applicants include a wide range of organizations, with funding amounts reaching up to $900,000 per year, and applications are due by May 16, 2028. For further inquiries, interested parties can contact Kimberly Pendleton at Kimberly.Pendleton@fda.hhs.gov.
    Forecast to Publish a Notice of Funding Opportunity (NOFO) for NCI Community Oncology Research Program (NCORP) Research Bases (UG1 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is set to publish a Notice of Funding Opportunity (NOFO) for the NCI Community Oncology Research Program (NCORP) Research Bases, which requires clinical trials. This initiative aims to enhance the generalizability and dissemination of clinical trial results by engaging cancer patient populations and organizations in rigorous studies focused on cancer control, prevention, treatment, and care delivery. The program will support seven awards with an estimated total funding of $60 million, and applications are open to small businesses. Interested applicants should note that the synopsis is expected to be posted on August 29, 2025, with a closing date for applications on November 14, 2025, and the anticipated award date is August 1, 2026. For further inquiries, contact Brandy Heckman-Stoddard, Ph.D., M.P.H., at 240-276-7048 or via email at heckmanbm@mail.nih.gov.
    Forecast to Publish a Notice of Funding Opportunity for The Metastasis Research Network (MetNet): MetNet Research Projects (U01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the Metastasis Research Network (MetNet), specifically targeting research projects under the U01 Clinical Trial Not Allowed funding mechanism. This initiative aims to solicit applications that utilize integrative systems-level approaches to address critical questions in metastasis research, aligning with the ongoing efforts of the MetNet, which focuses on understanding the complex dynamics of metastasis through collaborative research. The anticipated NOFO is expected to be published in Summer 2025, with applications due in Fall 2025, and will support approximately 10 awards, with no cost-sharing or matching requirements. For further inquiries, interested applicants can contact Joanna M. Watson, Ph.D., at watsonjo@mail.nih.gov or by phone at 240-276-6206.
    Notice of Intent to Publish the re-issuance of the Notice of Funding Opportunity (NOFO) Rare Diseases Clinical Research Consortia (RDCRC) for the Rare Diseases Clinical Research Network (RDCRN) (U54 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is set to re-issue the Notice of Funding Opportunity (NOFO) for the Rare Diseases Clinical Research Consortia (RDCRC) under the Rare Diseases Clinical Research Network (RDCRN), aimed at enhancing research in the diagnosis, management, and treatment of rare diseases. Each RDCRC is required to focus on at least three rare diseases and propose two to four clinical research projects, including one longitudinal study, emphasizing a collaborative, multi-site approach to address significant clinical trial readiness gaps. This initiative reflects the government's commitment to advancing public health through innovative methodologies and stakeholder engagement in the rare disease domain, with applications expected to be due in June and fall of 2025. Interested applicants can reach out to Dr. Tiina K. Urv at 301-827-2746 or via email at urvtiin@mail.nih.gov for further information.
    BROAD AGENCY ANNOUNCEMENT (BAA) for Extramural Biomedical and Human Performance Research and Development Department of Defense
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research Acquisition Activity (USAMRAA), has announced a Broad Agency Announcement (BAA) for Extramural Biomedical and Human Performance Research and Development. This opportunity invites unrestricted applicants to submit proposals aimed at advancing biomedical research and development, with a focus on enhancing human performance. The program is critical for fostering innovation in science and technology, particularly in areas that support the Department of Defense's mission. The estimated total program funding is $10 million, with individual awards ranging from $750,000 to $50 million, and proposals are due by July 31, 2028. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507.
    Notice of Intent to Publish a Funding Opportunity Announcement for the Rare Diseases Clinical Research Consortia (RDCRC) for the Rare Diseases Clinical Research Network (RDCRN)
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Funding Opportunity Announcement (FOA) for the Rare Diseases Clinical Research Consortia (RDCRC) as part of the Rare Diseases Clinical Research Network (RDCRN). This initiative aims to enhance the diagnosis, management, and treatment of rare diseases through collaborative, multi-site, patient-centric research, with a focus on addressing unmet clinical trial readiness needs. The estimated total program funding for this opportunity is $1,000,000, with the FOA expected to be published in 2024 and applications due later that year. Interested applicants can reach out to Dr. Tiina K. Urv at 301-827-2746 or via email at urvtiin@mail.nih.gov for further information.